SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Trump Buys SpaceX Shares After Record IPO 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Add as a preferred source on Google
BRIDGEWATER, N.J., May 01, 2018 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will present at the Deutsche Bank 43rd Annual Health Care Conference in Boston, MA on Tuesday, May 8, 2018 at 4:10 p.m. EDT.
The presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical Company focused on the unmet needs of patients with rare diseases. The Company’s lead product candidate is ALIS, which is in late-state development for adult patients with treatment refractory NTM lung disease caused by MAC, which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.
Contact:
Blaine Davis
Insmed Incorporated
(908) 947-2841
[email protected]
